Program
MG1111
A development code. Also written as “MG1111 (Barycela inj.)” and “MG1111 (BARICELA)”.
Its studies are mostly in Chickenpox, led by GC Biopharma.
Furthest: phase 3, since Jul 7, 20254 company-led studies, 2 open or runningNext primary completion: Aug 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GC Biopharma | 42 open or running | phase 3since Jul 7, 2025 | Feb 12, 2015 | Aug 2027phase 3 · NCT07054099 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 12, 2015First study: phase 1 study in ChickenpoxFirst studyNCT02367638 · 39 enrolled
- May 24, 2022Phase 2 study in ChickenpoxNCT05422508 · 230 planned · Korea, Republic of
- Dec 2, 2022No phase study in Varicella Zoster Virus InfectionNCT05664152 · 250 enrolled
- Jul 7, 2025Phase 3 study in ChickenpoxNCT07054099 · 474 planned · Thailand
Ahead
- Aug 2027Primary completion: phase 3 study in ChickenpoxNCT07054099
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07054099Chickenpox · Thailand | 3 | Recruiting | Aug 2027 | 474 |
| NCT05664152Varicella Zoster Virus Infection | – | UNKNOWN | Apr 2023 | 250 |
| NCT05422508Chickenpox · Korea, Republic of | 2 | Recruiting | Jun 2025 | 230 |
| NCT02367638Chickenpox | 1 | Completed | Jul 2015 | 39 |
How it is read
Names in the registry
- “MG1111”, 2 entries
- “MG1111 (Barycela inj.)”, 1 entry
- “MG1111 (BARICELA)”, 1 entry
Codes read as this program: MG1111.
Conditions, from the studies’ own filings
- Chickenpox, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.